SAN DIEGO and SUZHOU, China, Oct. 11, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a pioneering company in the development of novel antibody-based therapies, has announced that it will showcase clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, set to take place from November 8-12 in Boston.
Adagene’s innovative NEObody technology platform facilitates dynamic targeting of a specific epitope of CTLA-4, aiming to enhance both safety and efficacy. The upcoming poster presentations will highlight the differentiated safety profile of ADG116, showcasing results from heavily pre-treated patients receiving repeat doses as both monotherapy and in combination with anti-PD-1 therapy.

Notable details from the posters include:

Title: A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
Date: Thursday, November 10, 2022
Poster Session: 9:00 a.m. – 9:00 p.m. Eastern Time (ET)
Location: Poster Hall
Abstract Poster Number: 753

Title: A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update
Date: Thursday, November 10, 2022
Poster Session: 9:00 a.m. – 9:00 p.m. ET
Location: Poster Hall
Abstract Poster Number: 773

Both posters will be accessible on Adagene’s website at www.adagene.com/pipeline/publications following the SITC embargo policy on November 10, 2022.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage biotechnology company focused on transforming the discovery and development of novel antibody-based cancer immunotherapies. By integrating computational biology and artificial intelligence, Adagene aims to design antibodies that meet unmet patient needs. The company’s proprietary Dynamic Precision Library (DPL) platform, featuring NEObody™, SAFEbody®, and POWERbody™ technologies, underpins its differentiated pipeline of immunotherapy programs. Adagene has established strategic partnerships with leading global organizations to advance its innovative technologies.